{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"157","value":"2"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"419","value":"3"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"19","value":"0"},{"comment":"Only 1 participant was analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"84"},{"groupId":"OG004","lowerLimit":"1","upperLimit":"2","value":"2"}]}],"title":"Cycle 5 Day 1 (n=15,13,19,1,2)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"90","value":"1"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"22","value":"2"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"5","value":"1"},{"comment":"Only 1 participant was analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"27"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Cycle 6 Day 1 (n=15,14,18,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"113","value":"2"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"8","value":"2"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"7","value":"0"},{"comment":"Only 1 participant was analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"7"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 28 Day Visit (n=15,11,19,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"215","value":"1"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"42","value":"3"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"2","value":"0"},{"comment":"Only 1 participant was analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"14"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 56 Day Visit (n=15,9,15,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"469","value":"3"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"5","value":"1"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"6","value":"1"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 3 Month Visit (n=16,8,18,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"5929","value":"2"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"265","value":"1"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"96","value":"2"},{"comment":"Only 1 participant was analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"51"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 6 Month Visit (n=15,13,17,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"15727","value":"66"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"728","value":"19"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"1153","value":"29"},{"comment":"Only 1 participant was analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"74"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 9 Month Visit (n=15,13,15,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"1457","value":"126"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"2775","value":"31"},{"groupId":"OG002","lowerLimit":"2","upperLimit":"1281","value":"90"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 12 Month Visit (n=14,14,20,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"2426","value":"175"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"6588","value":"41"},{"groupId":"OG002","lowerLimit":"29","upperLimit":"500","value":"106"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 15 Month Visit (n=14,11,15,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"5871","value":"175"},{"groupId":"OG001","lowerLimit":"16","upperLimit":"13749","value":"82"},{"groupId":"OG002","lowerLimit":"22","upperLimit":"478","value":"189"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 18 Month Visit (n=13,14,15,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27","upperLimit":"10679","value":"128"},{"groupId":"OG001","lowerLimit":"9","upperLimit":"314","value":"78"},{"groupId":"OG002","lowerLimit":"57","upperLimit":"783","value":"149"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 21 Month Visit (n=13,12,16,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29","upperLimit":"11989","value":"238"},{"groupId":"OG001","lowerLimit":"25","upperLimit":"2225","value":"110"},{"groupId":"OG002","lowerLimit":"69","upperLimit":"1343","value":"232"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"FU 24 Month Visit(n=12, 4,16,0,0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"CD 19 is a surface antigen (protein) present on B-lymphocytes.","dispersionType":"Full Range","groups":[{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1400 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 1: Rituximab SC 1400 Milligrams (mg)"},{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1600 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG001","title":"Part 1: Rituximab SC 1600 mg"},{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1870 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG002","title":"Part 1: Rituximab SC 1870 mg"},{"description":"One participant enrolled in the rituximab SC 1870 mg subcohort received 1000 mg rituximab SC during Cycle 6 in error.\n\nParticipant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1000 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG003","title":"Part 1: Rituximab SC 1000 mg"},{"description":"These participants were withdrawn prior to SC treatment.","id":"OG004","title":"Part 1: No SC Dose Received"}],"paramType":"MEDIAN","populationDescription":"Part 1 SAP; n = number of participants analyzed at the specified visit.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15,18, 21 and 24","title":"Part 1: Total Cluster Differentiation19 Positive (CD19+) B-Cell Counts by Visit","type":"SECONDARY","unitOfMeasure":"cells per microliter (cells/μL)"}